Wetherby Asset Management Inc Prothena Corp Public LTD CO Transaction History

Wetherby Asset Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$48.26 - $78.59 $172,288 - $280,566	3,570 New	3,570 $243,000
Q4 2022 Feb 14, 2023	SELL	$52.05 - $65.0 $168,746 - $210,730	-3,242 Reduced 45.78%	3,840 $231,000
Q3 2022 Nov 14, 2022	SELL	$25.16 - $60.63 $50,320 - $121,260	-2,000 Reduced 22.02%	7,082 $429,000
Q2 2022 Aug 15, 2022	BUY	$22.73 - $39.98 $56,825 - $99,949	2,500 Added 37.98%	9,082 $247,000
Q1 2022 May 16, 2022	BUY	$30.27 - $49.22 $199,237 - $323,966	6,582 New	6,582 $241,000
Q4 2021 Feb 14, 2022	SELL	$42.11 - $73.26 $164,481 - $286,153	-3,906 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$48.2 - $78.89 $35,716 - $58,457	-741 Reduced 15.95%	3,906 $278,000
Q2 2021 Aug 16, 2021	BUY	$21.63 - $57.65 $100,514 - $267,899	4,647 New	4,647 $239,000

185

42.8M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $668M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Wetherby Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Wetherby Asset Management Inc with notifications on news.